Skip to content
Clinical ResearchResearch compoundLimited evidence

ASP‑4345

Experimental drug candidate for the thinking problems linked to schizophrenia; not proven in humans, development stopped.

NootropicModulatorDopaminergicMemoryFocusDopaminenoo.affects.memorynoo.affects.focus

Pharmacology

ClassDopaminergic · Memory · Focus
Primary targetDopamine D1 receptor positive allosteric modulation
Targets3 receptor targets
Half-lifeElimination half-life ~9.1-26.8 hours (Phase 1 human studies)
OnsetPeak plasma levels in ~1-3 hours (oral); designed for once-daily dosing
EvidenceLimited evidence
Affected systemsDopaminenoo.affects.memorynoo.affects.focus

Contents

DETAILED OVERVIEW

What is ASP-4345?

ASP-4345 is an experimental drug candidate that a drug company developed as an add-on treatment for the thinking and attention problems (cognitive impairment) linked to schizophrenia. It is not an approved medicine or a dietary supplement; development was stopped after the second phase of trials.

It does not switch on one of the brain's dopamine-signaling receptors directly, but amplifies the brain's own dopamine response, mainly in the front part of the cortex; this was meant to avoid the heart and seizure risks of direct activators. Only early, small human studies were done: the most common side effects were mild headache and drowsiness, and cognitive tests showed improvement, but its effect is not proven. Nothing is known about its long-term safety. Its safety in pregnancy and breastfeeding has not been shown.

Mechanism

Dopamine D1 receptor PAM (allosteric)

Half-life

~9-27 h (once-daily dosing)

Legal status

Investigational (halted at Phase 2)

Receptor profile

  • Dopamine D1 receptorModerate
  • Prefrontal cognitive circuitsWeak
  • Auditory information processingWeak

Safety

Side effects, stop signs, contraindications

Side effects · 4

  • Headache, the most common and typically mild adverse effect in trials
  • Somnolence (drowsiness), mostly mild in severity
  • Limited human safety database: only Phase 1 and Phase 2 studies were run, in small patient numbers
  • Long-term safety is unknown because development was halted at Phase 2

Contraindications · 3

  • Not an approved medicine: not authorized for human use, studied only in a research context
  • Pregnancy and breastfeeding: safety not established, avoid
  • In trials it was given as add-on to antipsychotics in schizophrenia; there is no data for standalone unsupervised use

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

ASP-4345 is an experimental drug candidate that has been studied for improving cognitive problems, such as attention and psychomotor function, in patients with schizophrenia. It's important to stress this is not an available, established substance but a research-stage compound with no data on safety or effects in healthy people.

Telegram

Have a question about ASP‑4345?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC19H14ClF3N4O3
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.